GI Insights

The Updated Role of Non-Invasive Biomarkers in MASLD

11.21.2023 - By ReachMDPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Host: Peter Buch, MD, FACG, AGAF, FACP

Guest: Julia J Wattacheril, MD, MPH

Non-invasive biomarkers for metabolic dysfunction-associated steatosis liver disease (MASLD) are used to stratify risk and assess disease severity in our patients. In this episode, Dr. Peter Buch is joined by Dr. Julia Wattacheril, Associate Professor of Medicine at Columbia University Irving Medical Center, to discuss the American Gastroenterological Association’s clinical practice update on the role of noninvasive biomarkers in MASLD.

More episodes from GI Insights